pH Pharma presents ADC proof-of-concept study results at AACR Annual Meeting

pH Pharma announced proof-of-concept (POC) study results on an antibody-drug conjugate (ADC) containing PH1, pH Pharma's novel toxin payload, at the Association for Cancer Research Annual Meeting April 10-14th, 2021 (AACR 2021). The study demonstrated the potential of PH1 as a potent anti-cancer warhead with immune-stimulatory effects. Highlights: Promising platform...

pH Pharma IND approval for “Alpha-1 Antitrypsin Deficiency treatment” Phase 2 clinical trial in Europe

PH Pharma, an innovative new drug research and development company, recently received final approval from the UK and Ireland authorities for the Phase 2 Clinical Trial to develop PHP-303 as the treatment for alpha-1 antitrypsin deficiency.(For more information, please refer to the link below)https://www.edaily.co.kr/news/read?newsId=02745366625637392 

pH Pharma passed technical evaluation

Received “Pass” from two tech evaluation agencies… Target to file preliminary review application to KOSDAQExpanding global new drug development platform through IPO. Accelerating innovation for new drug development and business development(For more information, please refer to the link below)https://www.hankyung.com/it/article/201912276015i